PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial
Portfolio Pulse from Juan Spínelli
PharmAla Biotech Holdings Inc. (OTC:MDXXF) will supply the University of Texas, San Antonio with a novel MDMA dosage form for a clinical trial. The company also announced a new patent application for its APA-01 molecular entity.
October 08, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PharmAla Biotech is supplying a novel MDMA dosage form for a clinical trial at the University of Texas, San Antonio, and has filed a new patent application for APA-01.
The partnership with a reputable institution like the University of Texas, San Antonio, for a clinical trial could enhance PharmAla's credibility and market position. Additionally, the new patent application for APA-01 strengthens its intellectual property portfolio, potentially increasing investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90